Journal of Clinical Laboratory Analysis · 2017 · 21 citations · 12 references
MedicineClinical PharmacokineticsPharmacologyCancer PharmacologyChemotherapyMass Spectrometric AnalysisAssay ValidationBioanalytical Method ValidationBiomarker ValidationMass SpectrometryOncology PharmacologyPharmacokinetics Of Anticancer DrugsConcentrationIrinotecan-based TherapyLiquid Chromatography-mass SpectrometryLiquid Chromatography-mass Spectrometry AnalysisMultiple Reaction MonitoringPharmacokinetics Of Cytotoxic ChemotherapyProtein PrecipitationQuantitative Assay Validation
BACKGROUND: Irinotecan (CPT-11) is chemotherapy used mainly in the metastatic colorectal cancer. The purpose of this study was to develop and validate the LC-MS/MS for the simultaneous determination of CPT-11, SN-38, and SN-38G. METHODS: A 100 μL of plasma was prepared after protein precipitation and analyzed on a C18 column using 0.1% acetic acid in water and 0.1% acetic acid in acetonitrile as mobile phases. The mass spectrometer worked with multiple reaction monitoring (MRM) in positive scan mode. The standard curves were linear on a concentration range of 5-10 000 ng/mL for CPT-11, 5-1000 ng/mL for SN-38, and 8-1000 ng/mL for SN-38G. RESULTS: In this assay, the intra and interday precision consisted of ≤9.11% and ≤11.29% for CPT-11, ≤8.70% and 8.31% for SN-38, and ≤9.90 and 9.64% for SN-38G. CONCLUSION: This method was successfully used to quantify CPT-11, SN-38, and SN-38G and applied to a pharmacokinetic study.
12
Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).
Ron H.J. Mathijssen, R J van Alphen, Jaco J. Verweij et al. · PubMed · 2001 · 752 citations · Full text
Medicine, Oncology, Pharmacology +17
UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity
Lalitha Iyer, Soma Das, Linda Janisch et al. · The Pharmacogenomics Journal · 2002 · 712 citations
Phase I and pharmacokinetic trial of weekly CPT-11.
Mace L. Rothenberg, John G. Kuhn, Howard A. Burris et al. · Journal of Clinical Oncology · 1993 · 303 citations
Medicine, Oncology, Pharmacology +16